



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

12
9/10/03
RECEIVED
AUG 27 2003

TECH CENTER 1501 124 16

Application of: Gavin C. Hirst et al.

Serial No.: 09/815,310 ✓

ART UNIT: 1624

Filed: March 22, 2001 ✓

EXAMINER: Habte, K.

Entitled: PYRAZOLOPYRIMIDINES AS
THERAPEUTIC AGENTS ✓

Attorney Docket No.: BBC-072/B

Mail Stop Non Fee Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

**INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR §§ 1.56, 1.97 AND 1.98**

Sir/Madam:

In accordance with the duty of disclosure under 37 CFR § 1.56, Applicants submit this Information Disclosure Statement pursuant to 37 CFR §§ 1.97 and 1.98 for the above-identified application. Applicants makes the following publications of record in the above-identified application.

U.S. Patent Application Documents

Hirst *et al.*, U.S. Serial No. 09/663,320; Filed September 15, 2000

Hirst *et al.*, U.S. Serial No. 09/663,780; Filed September 15, 2000

Hirst *et al.*, U.S. Serial No. 10/104,140; Filed March 22, 2002

Form PTO-1449 listing each of these documents and photocopies of each document are enclosed herewith for the Examiner's convenience.

This paper is being mailed before the mailing of a first office action on the merits in the above-identified application filed under 35 U.S.C §111 and 37 CFR §1.53(b). Pursuant to 37 CFR §1.97(b)(1), no fee is required with this submission.

Applicant does not intend to represent that any of the documents submitted herein is material prior art to this invention or that the list represents an exhaustive search of documents related to this invention.

Applicant respectfully requests that the documents submitted herein be considered and made of record in this application.

Respectfully submitted,

A handwritten signature in cursive script, reading "Gayle B. O'Brien", followed by a checkmark.

Gayle B. O'Brien
Agent for Applicant
Registration No. 48,812
Abbott Bioresearch Center, Inc.
100 Research Drive
Worcester, MA 01605-4314
Telephone: (508) 688-8053
Telefax: (508) 688-8110



08-25-03

1624

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

AUG 27 2003

TECH CENTER 1600/2906

Application of: Gavin C. Hirst et al.

Serial No.: 09/815,310

ART UNIT: 1624

Filed: March 22, 2001

EXAMINER: Habte, K.

Entitled: PYRAZOLOPYRIMIDINES AS
THERAPEUTIC AGENTS

Atty. Docket No.: BBC-072/B

Mail Stop Non Fee Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450**CERTIFICATE OF MAILING BY "EXPRESS MAIL"**

The undersigned hereby certifies that the correspondence listed below is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" Service under 37 CFR §1.10, postage prepaid, Express Mailing Label No. EU509624007US, in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date indicated below.

August 22, 2003
date of mailing and signatureLisa Rasmussen
Lisa Rasmussen**TRANSMITTAL LETTER**

Sir/Madam:

Transmitted herewith are: [X] Reply Under 37 C.F.R. §1.111 with Exhibit A; [X] An Information Disclosure Statement under 37 CFR §§ 1.56, 1.97 and 1.98; [X] Form PTO-1449 Information Disclosure Statement; [X] A photocopy of each reference cited; and [X] An Acknowledgement Postcard to be filed in the above-identified patent application.

FEE FOR ADDITIONAL CLAIMS

[X] A fee for additional claims is not required.

[] A fee for additional claims is required. The additional fee has been calculated as shown below:

	CLAIMS REMAINING AFTER AMENDMENT	HIGHEST NUMBER PREVIOUSLY PAID FOR	NUMBER OF EXCESS CLAIMS	RATE	FEE DUE
TOTAL CLAIMS	28	45	0	× \$18	= 0.00
INDEPENDENT	6	8	0	× \$84	= 0.00
FIRST INTRODUCTION OF MULT. DEPENDENT CLAIM				+\$280	= 0.00
TOTAL FEES DUE					= 00.00


PAYMENT OF ADDITIONAL FEES

- [X] The Commissioner is hereby authorized to charge payment of any additional fees required under 37 CFR 1.16 or 1.17 in connection with the paper(s) transmitted herewith, or to credit any overpayment of same, to **Deposit Account No. 010025**. A duplicate copy of this transmittal letter is transmitted herewith.

PETITION FOR EXTENSION OF TIME

- [X] Extension is requested under 37 CFR 1.136(a), and the following extension fee is applicable for the paper(s) filed herewith:
- ☐ \$110.00 for response within first month pursuant to 37 CFR 1.17(a)(1);
 - ☐ \$410.00 for response within second month pursuant to 37 CFR 1.17(a)(2);
 - ☐ \$930.00 for response within third month pursuant to 37 CFR 1.17(a)(3);
 - ☐ \$1,450.00 for response within fourth month pursuant to 37 CFR 1.17(a)(4);
 - ☐ \$1,970.00 for response within fifth month pursuant to 37 CFR 1.17(a)(5);
- [X] The Commissioner is hereby authorized to charge payment of any fees required in connection with the paper(s) transmitted herewith, or to credit any overpayment of same, to **Deposit Account No. 010025**. A duplicate copy of this transmittal letter is transmitted herewith.

Respectfully submitted,



Gayle B. O'Brien
Agent for Applicants
Reg. No. 48,812
Abbott Bioresearch Center, Inc.
100 Research Drive
Worcester, MA 01605
(508) 688-8053

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

AUG 22 2003

Docket Number (Optional)

BBC-072/

Application Number

09/815,310

Applicant(s)

Gavin C. Hirst

Filing Date

March 22, 2001

Group Art Unit

1624

*EXAMINER
INITIAL

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

Gavin C. Hirst et al., U.S. Serial Number 10/104,140; Filed March 22, 2002

RECEIVED
RECEIVED
AUG 27 2003

AUG 27 2003
TECH CENTER 1600/2300

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.